Hospital admissions due to exacerbations: number of participants · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in patients with exacerbations causing hospitalisation compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Rate of exacerbations requiring systemic corticosteroids · adults with asthma not well controlled on ICS
Single inhaler therapy leads to lower patients with exacerbations treated with oral steroids compared with fixed dose ICS (high certainty).
1 finding from 1 review
Fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in fatal serious adverse events compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Non‐fatal serious adverse events · adults with asthma not well controlled on ICS
Single inhaler therapy showed no clear difference in serious adverse events (non‐fatal) compared with fixed dose ICS (moderate certainty).
1 finding from 1 review
Participants with a serious adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with ≥ 1 adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with a serious adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with ≥ 1 adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with a serious adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with ≥ 1 adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with a serious adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with ≥ 1 adverse event following a single dose · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with ≥ 1 adverse event following a single dose, and after 3 to 5 days · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Participants with a serious adverse event following a single dose, and after 3 to 5 days · adults with moderate or severe acute postoperative pain
1 finding from 1 review
Overall survival (OS) · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower overall survival (OS) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
1‐Year survival rate (OS1y) · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower 1‐Year survival rate (OS1y) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Progression‐free survival · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to lower progression‐free survival compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Objective response rate · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher objective response rate (ORR) compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review
Grade 3 and 4 hematological adverse events (AE) ‐ anemia · non‐small cell lung cancer in the elderly population
It is very uncertain whether non‐platinum single‐agent changes grade 3 and 4 hematological adverse events (AE) ‐ anemia compared with non‐platinum combination treatment (very low certainty).
1 finding from 1 review
Grade 3 to 4 neutropenia · non‐small cell lung cancer in the elderly population
Non‐platinum single‐agent may leads to higher grade 3 and 4 hematological adverse events (AE) ‐ neutropenia compared with non‐platinum combination treatment (low certainty).
1 finding from 1 review